Cargando…

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does not achieve a maximal therapeutic effect, and some mutations confer resistance to current available agents. In the cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Gang, Kronenberger, Peter, Teugels, Erik, Umelo, Ijeoma Adaku, De Grève, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334713/ https://www.ncbi.nlm.nih.gov/pubmed/22436374 http://dx.doi.org/10.1186/1741-7015-10-28

Ejemplares similares

Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2020)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
por: Noor, Alfiah, et al.
Publicado: (2018)

miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
por: Chen, Gang, et al.
Publicado: (2013)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
por: Chen, Gang, et al.
Publicado: (2010)

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015)

Stromal Modulators of TGF-β in Cancer
por: Costanza, Brunella, et al.
Publicado: (2017)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors
por: Rozensztajn, Nathalie, et al.
Publicado: (2014)

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Chen, Qi, et al.
Publicado: (2015)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
por: Martin-Fernandez, Marisa L.
Publicado: (2022)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
por: Bencardino, K., et al.
Publicado: (2007)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
por: Zheng, Yuyan, et al.
Publicado: (2020)

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
por: Noeparast, Amir, et al.
Publicado: (2018)

Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
por: Fei, Shi-Jiang, et al.
Publicado: (2013)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Yoshida, Takeshi, et al.
Publicado: (2016)

Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
por: Xu, Jing, et al.
Publicado: (2017)

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Goag, Eun Kyong, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
por: Dong, Lijun, et al.
Publicado: (2017)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
por: Lan, Chou-Chin, et al.
Publicado: (2022)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Keam, Bhumsuk, et al.
Publicado: (2014)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
por: Wu, Jenn-Yu, et al.
Publicado: (2016)

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer
por: Jeong, Hyungmin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tgdmjklp89ha4ijr17quhmvtks